Search results for " liver transplantation"

showing 10 items of 68 documents

Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the…

2020

Abstract Background The COVID-19 pandemic had a huge impact on national and regional health systems. The impact of SARS-CoV-2 on the quality of care for patients with liver disease is still unknown. Aims The Italian Association for the Study of the Liver (AISF) conducted a survey to assess the impact of SARS-CoV-2 on hepatology units activities in Italy. Methods A prospective web-based survey was proposed to all AISF active members. The survey was available online from April 8 2020, to May 3 2020, (lockdown phase in Italy). Results 194 AISF members answered the questionnaire, most of whom were specialists in Gastroenterology (41%) or Internal Medicine (28%), and worked in Northern Italy (51…

Liver CirrhosisLiver disease0302 clinical medicineSurveys and QuestionnairesPandemicAmbulatory CareMass ScreeningParacentesisViralChronicLiver DiseasesLiver NeoplasmsGastroenterologyHepatology Covid-19 SARS COV-2Hepatitis BHepatitis CHospitalizationCovid-19; Hepatology; SARS COV-2Italy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyCoronavirus Infectionsmedicine.medical_specialtyCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralEsophageal and Gastric VaricesAntiviral AgentsArticle03 medical and health sciencesBetacoronavirusHepatitis B ChronicInternal medicinemedicineHumansPandemicsMass screeningQuality of Health CareHepatologybusiness.industrySARS-CoV-2SARS COV-2CarcinomaOutbreakCOVID-19HepatocellularPneumoniaHepatitis C ChronicHepatologymedicine.diseaseNorthern italyLiver TransplantationEmergency medicineChronic DiseaseCovid-19; Hepatology; SARS COV-2; Ambulatory Care; Antiviral Agents; Betacoronavirus; COVID-19; Carcinoma Hepatocellular; Chronic Disease; Coronavirus Infections; Esophageal and Gastric Varices; Gastroenterology; Hepatitis B Chronic; Hepatitis C Chronic; Hospitalization; Humans; Italy; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Liver Transplantation; Mass Screening; Pandemics; Paracentesis; Pneumonia Viral; Quality of Health Care; SARS-CoV-2; Surveys and Questionnairesbusiness
researchProduct

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrho…

2018

Background: In 2012, an Italian Named Patient Program began for hepatitis C virus (HCV)-infected liver transplant (LT) recipients with advanced fibrosis, before approval of direct antiviral agents (DAA), to benefit severely ill patients. The aim of this “real-life” study was to assess treatment efficacy and safety with an extended course of daclatasvir (DCV) plus sofosbuvir (SOF) with or without ribavirin (RBV). Methods: All HCV LT recipients with severe fibrosis in 15 Italian transplant centers were treated with DCV+SOF±RBV for 24 weeks; sustained virological response was assessed at 12 weeks post-treatment (SVR12). Results: Eighty-seven patients were enrolled (75.9% males, mean age 58.4 ±…

Liver CirrhosisMalehepatitis C virusPyrrolidinesCirrhosisSofosbuvirmedicine.medical_treatmentantiviral treatmentHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrencehepatitis C viruProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologialiver transplantationdirect antiviral agentsImidazolesValineHepatitis CMiddle AgedPrognosisHepatitis CItalyHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyDaclatasvirHepatitis C virusAntiviral Agentsantiviral treatment; cirrhosis; direct antiviral agents; hepatitis C virus; liver transplantation03 medical and health sciencesInternal medicineRibavirinmedicineHumansTransplantationdirect antiviral agentbusiness.industryRibavirincirrhosismedicine.diseasechemistryCarbamatesSofosbuvirbusinessFollow-Up Studiescirrhosi
researchProduct

Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

2014

SummaryThe burden of infectious diseases both before and after liver transplantation is clearly attributable to the dysfunction of defensive mechanisms of the host, both as a result of cirrhosis, as well as the use of immunosuppressive agents.The present document represents the recommendations of an expert panel commended by the Italian Association for the Study of the Liver (AISF), on the prevention and management of infectious complications excluding hepatitis B, D, C, and HIV in the setting of liver transplantation.Due to a decreased response to vaccinations in cirrhosis as well as within the first six months after transplantation, the best timing for immunization is likely before transp…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentLiver transplantationInfectionsInvasive fungal infectionPostoperative ComplicationsBacterial infectionsInvasive fungal infectionsTransplantation ImmunologyLower respiratory tract infectionHumansMedicineSmallpoxVoluntary Health AgenciesIntensive care medicineImmunosuppression TherapyViral infectionsInfection ControlCirrhosiLiver transplantationAttenuated vaccineHepatologybusiness.industryVaccinationHepatitis Bmedicine.diseaseVaccinationTransplantationBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infections; Humans; Immunosuppression; Infection; Infection Control; Italy; Liver Cirrhosis; Liver Transplantation; Postoperative Complications; Transplantation Immunology; Vaccination; Voluntary Health Agencies; HepatologyCirrhosisItalyViral infectionBacterial infections; Cirrhosis; Invasive fungal infections; Liver transplantation; Viral infectionsAISFImmunologyBacterial infectionInfectionbusinessImmunosuppression
researchProduct

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

2018

ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportiona…

Male0301 basic medicineOncologyCandidate geneCholangitismedicine.medical_treatmentMedizinTrasplantament hepàticGenome-wide association studyKaplan-Meier EstimateLIVER FIBROSISLiver transplantationBioinformaticsSclerosingOral and gastrointestinalPrimary sclerosing cholangitis; genetics; liver transplantationCohort StudiesACTIVATION0302 clinical medicineMED/12 - GASTROENTEROLOGIAMULTIPLE2.1 Biological and endogenous factorsEPIDEMIOLOGYgeneticsAetiologyCIRRHOSISliver transplantationBilious diseases and biliousnessPrimary sclerosing cholangitisLiver Diseasedigestive oral and skin physiologyGastroenterologySingle NucleotidePrimary sclerosing cholangitiMiddle Aged3. Good healthULCERATIVE-COLITISDisease ProgressionFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyCholangitis SclerosingChronic Liver Disease and CirrhosisClinical SciencesMalalties del tracte biliarSingle-nucleotide polymorphismHEPATIC STELLATE CELLSPolymorphism Single NucleotideInternational PSC Study GroupArticlePrimary sclerosing cholangitisPaediatrics and Reproductive Medicine03 medical and health sciencesRare DiseasesClinical ResearchInternal medicineGeneticsmedicineHumansPolymorphismGENOME-WIDE ASSOCIATIONAlleleDigestive Diseases - (Gallbladder)Survival analysisProportional Hazards ModelsMALIGNANCYThe UK PSC ConsortiumTransplantationGastroenterology & Hepatologybusiness.industryProportional hazards modelmedicine.diseaseRISK LOCILogistic Models030104 developmental biology3121 General medicine internal medicine and other clinical medicinegeneticHepatic transplantationThrombospondinsDigestive DiseasesbusinessGenèticaGut
researchProduct

Progressive necrotic encephalopathy following tacrolimus therapy for liver transplantation.

2009

Previously described neurologic damage induced by immunosuppressive treatments includes transient or reversible central nervous system involvement. We describe a 57-year-old man who underwent liver transplantation and was started on immunosuppressive therapy with tacrolimus (FK506). Six months later, he started complaining of a progressive motor and sensory impairment of the left side, together with cognitive impairment. Brain MRI showed an enlarging lesion of the white matter with peripheral contrast enhancement. PET study indicated severe hypometabolism in the right hemisphere and spectroscopic MRI showed a peak of choline and relative reduction of other metabolites. Findings of CSF exami…

MalePathologymedicine.medical_specialtyNeurologyMagnetic Resonance Spectroscopymedicine.medical_treatmentEncephalopathyDermatologyBrain damageLiver transplantationTacrolimusWhite PeopleWhite matterLesionNecrosisProgressive necrotic encephalopathy liver transplantation.MedicineHumansHepatitis ChronicBrain Diseasesbusiness.industrySettore MED/27 - NeurochirurgiaBrainGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTacrolimusLiver TransplantationPsychiatry and Mental healthmedicine.anatomical_structurePositron-Emission TomographyDisease ProgressionSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerymedicine.symptombusinessImmunosuppressive AgentsFollow-Up StudiesNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
researchProduct

Methylene blue–aided cholangioscopy unravels the endoscopic features of ischemic-type biliary lesions after liver transplantation

2007

MalePathologymedicine.medical_specialtyOrthotopic liver transplantationBiliary Tract Diseasesmedicine.medical_treatmentIschemiaLiver transplantationLesionchemistry.chemical_compoundIschemiamedicineHumansRadiology Nuclear Medicine and imagingEndoscopy Digestive Systemmedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseLiver TransplantationEndoscopyMethylene BlueBiliary Tract Surgical ProceduresChromogenic CompoundschemistryBiliary tractEndoscopic retrograde cholangiographymedicine.symptombusinessCholangiographyMethylene blueGastrointestinal Endoscopy
researchProduct

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study

2022

There is increasing evidence that early liver transplantation (eLT), performed within standardized protocols can improve survival in severe alcoholic hepatitis (sAH). The aim of the study was to assess outcomes after eLT for sAH in four Italian LT centers and to compare them with non-responders to medical therapy excluded from eLT. Patients admitted for sAH (2013–2019), according to NIAAA criteria, were included. Patients not responding to medical therapy were placed on the waiting list for eLT after a strict selection. Histological features of explanted livers were evaluated. Posttransplant survival and alcohol relapse were evaluated. Ninety-three patients with severe AH were evaluated (65…

Maleclinical decision-makingTransplantationWaiting Listsalcoholism and substance abuseHepatitis AlcoholicPatient SelectionalllocationSettore MED/09 - MEDICINA INTERNAalcoholism and substance abuse; clinical decision-making; clinical research/practice; liver transplantation/hepatologyalcoholic hepatitiMiddle Agedclinical research/practiceLiver TransplantationRecurrenceMED/18 - CHIRURGIA GENERALEHumansImmunology and AllergyFemaleethicPharmacology (medical)Liver transplantliver transplantation/hepatologyAmerican Journal of Transplantation
researchProduct

Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic Comparison

2006

OBJECTIVE. The aims of this study were to determine the feasibility and efficacy of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma waiting for liver transplantation and to compare the radiologic and pathologic findings. SUBJECTS AND METHODS. Twenty-six patients with 35 hepatocellular carcinomas were addressed for transplantation. Complications of the procedures were recorded. Primary and secondary technique effectiveness and causes of exclusion from the waiting list were assessed. After transplantation, tumor recurrence was evaluated for at least 1 year in all patients. Radiologic-pathologic comparison of the explant was performed. RESULTS. Percutaneous radio…

Malemedicine.medical_specialtyCarcinoma HepatocellularPercutaneousRadiofrequency ablationmedicine.medical_treatmentLiver transplantationlaw.inventionlawPreoperative CaremedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyablation cancer hepatocellular carcinoma liver transplantation radiofrequencybusiness.industryLiver NeoplasmsCancerGeneral MedicineMiddle Agedmedicine.diseaseAblationLiver TransplantationSurgeryRadiographyTransplantationHepatocellular carcinomaCatheter AblationFeasibility StudiesFemaleRadiologybusinessFollow-Up StudiesAmerican Journal of Roentgenology
researchProduct